Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T11:02:23.665Z Has data issue: false hasContentIssue false
  • English
  • Français

MPTP-Induced Neurotoxicity and the Quest for a Preventative Therapy for Parkinson's Disease

Published online by Cambridge University Press:  18 September 2015

J.C.S. Furtado  and
Michael F. Mazurek
J.C.S. Furtado
Affiliation:
Division of Neuroscience, Department of Biomedical Sciences, McMaster University Medical Centre, Hamilton
Michael F. Mazurek*
Affiliation:
Division of Neuroscience, Department of Biomedical Sciences, McMaster University Medical Centre, Hamilton Division of Neurology, Department of Medicine, McMaster University Medical Centre, Hamilton
*
Neurology 4U2, McMaster University, Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Less than 10 years have passed since the discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is capable of producing parkinsonism in both humans and non-human primates. In that time, there has been considerable interest in the possibility that the pathogenesis of idiopathic Parkinson's disease (PD) might involve a process analogous to that of MPTP toxicity. One hypothesis holds that PD might arise, at least in part, from exposure to an MPTP-like environmental toxin. Rapid progress has been made towards elucidating the precise mechanism by which MPTP exerts toxicity, and clarifying the relationship of MPTP toxicity to idiopathic PD. The goal of these efforts is to develop a therapy that inhibits the underlying disease process in PD.

Type
Focus on Parkinson's Disease
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue 1 , February 1991 , pp. 77 - 82
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

1.Tetrud, JW, Langston, JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s Disease. Science 1989; 245: 519–522.CrossRefGoogle ScholarPubMed
2.Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s Disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
3.Birkmayer, W, Knoll, J, Riederer, P, et al. Increased life expectancy resulting from addition of deprenyl to madopar treatment in Parkinson’s disease: A long-term study. J Neural Transm 1985; 65: 113–127.CrossRefGoogle Scholar
4.Lees, AJ, Shaw, KM, Kohout, LJ, et al. Deprenyl in Parkinson’s dis-ease. Lancet 1977; 2: 791–795.CrossRefGoogle Scholar
5.Rinne, UK. Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1983; 95: 107–111.CrossRefGoogle ScholarPubMed
6.Csanda, E, Tarczy, M. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s Disease. Acta Neurol Scand Suppl 1983; 95: 117–122.CrossRefGoogle ScholarPubMed
7.Knoll, J. The possible mechanisms of action of (-) deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 177–198.CrossRefGoogle ScholarPubMed
8.Birkmayer, W, Knoll, J, Riederer, P, et al. (-) Deprenyl leads to pro-longation of L-dopa efficacy in Parkinson’s disease. Mod Prob in Pharmacopsych, 1983; 19: 170–176.Google Scholar
9.Langston, JW, Ballard, P, Tetrud, JW, et al. Parkinsonism due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle ScholarPubMed
10.Langston, JW, Irwin, I, Langston, EB, et al. MPTP-Induced parkin-sonism in humans: A review of the syndrome and observations relating to the phenomenon of tardive toxicity. In: Markey, SPet al. eds. MPTP: A neurotoxin producing a Parkinsonian syndrome. New York: Academic Press, 1986; 9–22.Google Scholar
11.Marini, AM, Schwartz, JP, Kopin, IJ. The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells. J Neurosci 1989; 9: 3665–3672.CrossRefGoogle ScholarPubMed
12.Forno, LS, Langston, JW, DeLanney, LE, et al. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449–455.CrossRefGoogle ScholarPubMed
13.Allen, MJ, Cross, AJ, Yeats, JC, et al. Neuropeptides and dopamine in the marmoset: Effect of treatment with l-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP). Brain 1986; 109: 143–157.CrossRefGoogle Scholar
14.Hallman, H, Lange, J, Olson, L, et al. Neurochemical and histochem-ical characterization of neurotoxic effects of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 1985; 44(1): 117–127.CrossRefGoogle Scholar
15.Heikkila, RE, Sonsalla, PK. The use of the MPTP-treated mouse as an animal model of Parkinsonism. Can J Neurol Sci, Suppl 1987; 14(3): 436–440.CrossRefGoogle ScholarPubMed
16.Sonsalla, PK, Heikkila, RE. The influence of dose and dosing inter-val on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 1986; 129: 339–345.CrossRefGoogle Scholar
17.German, GC, Dubach, M, Askari, S, et al. l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neurosci 1988; 24(1): 161–174.CrossRefGoogle Scholar
18.Melamed, E, Rosenthal, J, Globus, M, et al. Mesolimbic dopaminer-gic neurons are not spared by MPTP neurotoxicity in mice. Eur J Pharmacol 1985; 114: 97–100.CrossRefGoogle Scholar
19.Ghilardi, MF, Chung, E, Bodis-Wollner, I, et al. Systemic 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 1988; 43: 255–262.CrossRefGoogle Scholar
20.Forno, LS, DeLanney, LE, Irwin, I, et al. Neuropathology of MPTP-treated monkeys: Comparison with the neuropathology of human idiopathic Parkinson’s disease. In: Markey, SPet al, eds. MPTP: A Neurotoxin Producing a Parkinsonian Syndrome, New York: Academic Press 1986; 119–140.Google Scholar
21.Mitchell, IJ, Cross, AJ, Sambrook, MA, et al. Sites of the neurotoxic action of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett 1985; 61: 195–200.CrossRefGoogle Scholar
22.Mayer, RA, Kindt, V, Heikkila, RE. Prevention of the nigrostriatal toxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 1986; 47(4); 1073–1079.CrossRefGoogle Scholar
23.Chiba, K, Trevor, A, Castagnoli, N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984; 120(2): 574–578.CrossRefGoogle ScholarPubMed
24.Langston, JW. Mechanisms of MPTP toxicity: More answers, more questions. Trends Pharmacol Sci 1985; 6(9): 375–378.CrossRefGoogle Scholar
25.Fuller, RW, Hemrick-Luecke, SK. Influence of selective reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by l-methyl-4-phenyl-l,2,3,6-tetrahydropyri-dine in mice. Life Sci 1985; 37(12): 1089–1096.CrossRefGoogle Scholar
26.Heikkila, RE, Manzino, L, Cabbat, FS, et al. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467–469.CrossRefGoogle Scholar
27.Sundstrom, E, Jonsson, G. Pharmacological interference with the neurotoxic action of l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Eur J Pharmacol 1985; 110: 293–299.CrossRefGoogle Scholar
28.Mytilineou, C, Friedman, L. Studies on the metabolism and toxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in cultures of embryonic rat mesencephalon. J Neurochem 1988; 51: 750–755.CrossRefGoogle Scholar
29.Demarest, KT, Smith, DJ, Azzaro, AJ. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-con-taining neurons. J Pharmacol Exp Ther 1980; 215(2): 461–468.Google ScholarPubMed
30.Levitt, P, Pintar, JE, Breakfield, XO. Immunocytochemical demon-stration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci, USA 1982; 79: 6385–6389.CrossRefGoogle Scholar
31.Westlund, KN, Denney, RM, Kochersperger, LM, et al. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230: 181–183.CrossRefGoogle Scholar
32.Stenström, A, Sundström, E, Fowler, CJ. Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to neurotoxic actions of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pharmacol Toxicol 1989; 64: 276–281.CrossRefGoogle Scholar
33.Brooks, WJ, Jarvis, MF, Wagner, JC. Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker. J Neural Transm 1988; 71: 85–90.CrossRefGoogle ScholarPubMed
34.Brooks, WJ, Jarvis, MF, Wagner, JC. Astrocytes as a primary locus for the conversion of MPTP into MPP+. J Neural Transm 1989; 76: 1–12.CrossRefGoogle ScholarPubMed
35.Ransom, BR, Kunis, DM, Irwin, I, et al. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 1987; 75: 323–328.CrossRefGoogle ScholarPubMed
36.Javitch, JA, Snyder, SH. Uptake of MPP+ by dopamine neurons explains selectivity of Parkinsonism-inducing neurotoxin MPTP. Eur J Pharmacol 1984; 106: 455–456.CrossRefGoogle ScholarPubMed
37.Javitch, JA, D’Amato, RJ, Strittmatter, SM, et al. Parkinsonism-inducing neurotoxin, l-methyl-4-phenyl-l,2,3,6-tetrahydropyri-dine: Uptake of metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc Natl Acad Sci, USA 1985; 82: 2173–2177.CrossRefGoogle Scholar
38.Pileblad, E, Carlsson, A. Catecholamine-uptake inhibitors prevent the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyri-dine (MPTP) in mouse brain. Neuropharmacology 1985; 24(7): 689–692.CrossRefGoogle Scholar
39.Ricaurte, GA, Langston, JW, DeLanney, LE, et al. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 1985; 59: 259–264.CrossRefGoogle Scholar
40.Schinelli, S, Zuddas, A, Kopin, IJ, et al. l-methyl-4-pheny 1-1,2,3,6-tetrahydropyridine metabolism and l-methyl-4-phenylpyridini-um uptake in dissociated cell cultures from the embryonic mesencephalon. J Neurochem 1988; 50: 1900–1907.CrossRefGoogle Scholar
41.Fuller, RW, Hemrick-Luecke, SK, Perry, KW. Deprenyl antagonizes acute lethality of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther 1988; 247(2): 531–535.Google Scholar
42.Reinhard, JF, Daniels, AJ, Viveros, OH. Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) in the mouse: evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 1988; 90: 349–353.CrossRefGoogle Scholar
43.Barden, H. The biology and chemistry of neuromelanin. In Sohal, RS, ed. Age Pigments. Amsterdam: Elsevier, 1981: 155–180.Google Scholar
44.D’Amato, RJ, Alexander, GM, Schwartzman, RJ, et al. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987; 327: 324–326.CrossRefGoogle ScholarPubMed
45.D’Amato, RJ, Alexander, GM, Schwartzman, RJ, et al. Neuromelanin: A role in MPTP-induced neurotoxicity. Life Sci 1987; 40: 705–712.CrossRefGoogle ScholarPubMed
46.D’Amato, RJ, Benham, DF, Snyder, SH. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine, to neuromelanin. J Neurochem 1987; 48: 653–658.CrossRefGoogle Scholar
47.Levi, AC, DeMattei, M, Ravazzani, R, et al. Effects of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) on ultrastructure of nigral neuromelanin in Macaco fasckulahs. Neurosci Lett 1989; 96: 271–276.CrossRefGoogle Scholar
48.Bankiewicz, KS, Oldfield, EH, Chiueh, CC, et al. Hemiparkinsonism in monkeys after unilateral internal carotoid artery infusion of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986; 39(1): 7–16.CrossRefGoogle Scholar
49.Bédard, PJ, Di Paolo, T, Falardeau, P, et al. Chronic treatment with L-dopa, but not bromocriptine, induces dyskinesia in MPTP-parkinsonian monkeys: Correlation with [3H] spiperone binding. Brain Res 1986; 379: 294–299.CrossRefGoogle Scholar
50.Crossman, AR, Clarke, CE, Boyce, S, et al. MPTP-induced Parkinsonism in the monkey: Neurochemical pathology, complication of treatment and pathophysiological mechanisms. Can J Neurol Sci, Suppl 1987; 14(3): 428–435.CrossRefGoogle ScholarPubMed
51.Ramsay, RR, Singer, TP. Energy-dependent uptake of N-MPTP, by mitochondria. J Biol Chem 1986; 261: 7585–7587.CrossRefGoogle ScholarPubMed
52.Singer, TP, Ramsay, RR, McKeown, K, et al. Mechanism of the neu-rotoxicity of 1-methylphenylpyridinium (MPP+), the toxic bioactivation product of 1 -methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP). Toxicology 1988; 49: 17–23.CrossRefGoogle Scholar
53.Vyas, I, Heikkila, RE, Nicklas, WJ. Studies on the neurotoxicity of I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, l-methyl-4-phenylpyridinium. J Neurochem 1986; 46: 1501–1507.CrossRefGoogle Scholar
54.Schapira, AHV, Cooper, JM, Dexter, D, et al. Mitochondrial complex I deficiency in Parkinson’s Disease. J Neurochem 1990; 54: 823–827.CrossRefGoogle ScholarPubMed
55.Parker, WD, Boyson, SJ, Parks, JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989; 26: 719–723.CrossRefGoogle Scholar
56.Graham, D. On the origin and significance of neuromelanin. Arch Path Lab Med 1979; 103: 359–362.Google ScholarPubMed
57.Halliwell, B, Gutteridge, JMC. Free radicals in biology and medicine. Clarendon Press, Oxford. 1985.Google Scholar
58.Halliwell, B, Gutteridge, JMC. Oxygen free radicals and iron in rela-tion to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986; 246: 501–514.CrossRefGoogle Scholar
59.Halliwell, B, Gutteridge, JMC. Oxygen radicals and the nervous sys-tem. Trends Neurosci 1985; 8: 22–26.CrossRefGoogle Scholar
60.Perry, TL, Godin, DV, Hansen, S. Parkinson’s disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33: 305–310.CrossRefGoogle ScholarPubMed
61.Riederer, P, SoFic, E, Rausch, WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brain. J Neurochem 1989; 52: 515–520.CrossRefGoogle Scholar
62.Yong, VW, Perry, TL, Krisman, AA. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine. Neurosci Lett 1986; 63: 56–60.CrossRefGoogle Scholar
63.Earle, KM. Studies on Parkinson’s disease including X-ray fluores-cent spectroscopy of formalin-fixed brain tissue. J Neuropathol Exp Neurol 1968; 27: 1–14.CrossRefGoogle Scholar
64.Dexter, DT, Wells, FR, Agid, F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987; 5: 1219–1220.CrossRefGoogle Scholar
65.Pilas, B, Sana, T, Kalyanaraman, B, et al. The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Rad Biol Med 1988; 4: 285–293.CrossRefGoogle ScholarPubMed
66.Braughler, JM, Duncan, LA, Chang, RL. The involvement of iron in lipid peroxidation: Importance of feme to ferrous ratio in initiation. J Biol Chem 1986; 261: 10282–10289.CrossRefGoogle Scholar
67.Minotti, G, Aust, SD. The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide. J Biol Chem 1987; 262: 1098–1104.CrossRefGoogle ScholarPubMed
68.Willson, RL. Free radical protection: Why vitamin E, not vitamin C, beta-carotene or glutathione? In Biology of vitamin E. Ciba Foundation Symposium 101 1983; 19–44.Google Scholar
69.Duvoisin, RC. Is Parkinson’s disease acquired or inherited? Can J Neurol Sci Supplement 1984; 11(1): 151–155.CrossRefGoogle ScholarPubMed
70.Tanner, CM. The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci 1989; 12(2): 49–54.CrossRefGoogle ScholarPubMed
71.Langston, JW, Ballard, PA. Parkinson’s disease in a chemist working with l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. N Engl J Med 1983; 309–310.Google Scholar
72.Calne, DB, Langston, JW, Martin, WRW, et al. Positron emission tomography after MPTP: Observations relating to the cause of Parkinson’s disease. Nature 1985; 317: 246–249.CrossRefGoogle Scholar
73.Tetrud, JW, Langston, JW, Garbe, PL, et al. Mild parkinsonism in persons exposed to l-methyl-4-phenyl-l,2,3.6-tetrahydropyri-dine(MPTP). Neurology 1989; 39: 1483–1487.CrossRefGoogle Scholar
74.Perry, TL, Jones, K, Hansen, S, et al. 4-Phenylpyridine and three other analogues of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Neurosci Lett 1987; 75: 65–70.CrossRefGoogle Scholar
75.Perry, TL, Jones, K, Hansen, S, et al. 2-phenylpyridine and 3-phenylpyridine, constituents of tea.are unlikely to cause idiopathic Parkinson’s disease. J Neurol Sci 1988; 85: 309–317.CrossRefGoogle Scholar
76.Perry, TL, Yong, VW, Wall, RA, et al. Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 1986; 69: 285–289.CrossRefGoogle Scholar
77.Heikkila, RE, Kindt, MV, Sonsalla, PK, et al. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Nat Acad Sci, USA 1988; 85: 6172–6176.CrossRefGoogle Scholar
78.Koller, W, Vetere-Overfield, B, Gray, C, et al. Environmental risk factors in Parkinson’s disease. Neurology 1990; 40: 1218–1221.CrossRefGoogle ScholarPubMed
79.Teräväinen, H. Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333–336.CrossRefGoogle ScholarPubMed
80.Zweig, RM, Carmichael, JM, Morrill, GB. Deprenyl for the treatment of early Parkinson’s disease (letter). New Engl J Med 1990; 322: 1526.Google Scholar
81.Oreland, L, Johannson, F, Ekstedt, J. Dose regimen of deprenyl (selegiline) and platelet MAO activities. Acta Neurol Scand Suppl 1983;95:87–89.CrossRefGoogle ScholarPubMed
82.Arnett, DC, Fowler, JS, MacGregor, RR, et al. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C] deprenyl. J Neurochem 1987; 49: 522–527.CrossRefGoogle Scholar
83.Cohen, G, Spina, MB. Deprenyl suppresses the oxidative stress asso-ciated with increased dopamine turnover. Ann Neurol 1989; 26: 689–690.CrossRefGoogle Scholar